Zobrazeno 1 - 10
of 96
pro vyhledávání: '"FERNANDO BRIL"'
Autor:
Fernando Bril, Srilaxmi Kalavalapalli, Romina Lomonaco, Reginald Frye, Eddison Godinez Leiva, Kenneth Cusi
Publikováno v:
JHEP Reports, Vol 6, Iss 7, Pp 101092- (2024)
Background & Aims: It has been postulated that carriers of PNPLA3 I148M (CG [Ile/Met] or GG [Met/Met]) develop metabolic dysfunction-associated steatotic liver disease (MASLD) in the absence of insulin resistance or metabolic syndrome. However, the r
Externí odkaz:
https://doaj.org/article/c27cb77df685452e953139bddaf23c08
Autor:
Jennifer Girard, MD, Courtney Wagner, MD, Sujan Ravi, MD, Monica Agarwal, MD, MEHP, Fernando Bril, MD
Publikováno v:
AACE Clinical Case Reports, Vol 9, Iss 2, Pp 35-38 (2023)
Background: Lipoprotein X (LpX) is an abnormal lipoprotein composed of phospholipids, free cholesterol, and albumin. Its overaccumulation is an infrequent cause of hyperlipidemia, which oftentimes presents in patients with cholestatic liver disease.
Externí odkaz:
https://doaj.org/article/c2ce6169d9ee4a5ab0a3eda45e700c52
Publikováno v:
Metabolites, Vol 14, Iss 1, p 40 (2024)
This narrative review aims to illustrate the notion that nonalcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated steatohepatitis (MASH), is a systemic metabolic disorder featuring both adverse hepatic and extrahepatic o
Externí odkaz:
https://doaj.org/article/7dc9b6f65dae4d9f827df76c4b5d6fee
Autor:
Yonghui Wu, Xi Yang, Heather L Morris, Matthew J Gurka, Elizabeth A Shenkman, Kenneth Cusi, Fernando Bril, William T Donahoo
Publikováno v:
JMIR Medical Informatics, Vol 10, Iss 6, p e36997 (2022)
BackgroundNonalcoholic steatohepatitis (NASH), advanced fibrosis, and subsequent cirrhosis and hepatocellular carcinoma are becoming the most common etiology for liver failure and liver transplantation; however, they can only be diagnosed at these po
Externí odkaz:
https://doaj.org/article/6e2f3ab540304433a7cdde3e3bba7b5f
Autor:
Fernando Bril, MD
Publikováno v:
EBioMedicine, Vol 72, Iss , Pp 103584- (2021)
Externí odkaz:
https://doaj.org/article/fa3abe3bb54c4f4399d7a47108bf86ce
Autor:
Kristin Alexandra Dayton, Fernando Bril, Diana Barb, Jinping Lai, Srilaxmi Kalavalapalli, Kenneth Cusi
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0251449 (2021)
BackgroundHypogonadism is reported to occur in non-alcoholic fatty liver disease (NAFLD), but earlier studies used low-sensitivity diagnostic techniques (CT, ultrasound), for NAFLD diagnosis. We hypothesized that if hypogonadism was due to NAFLD, and
Externí odkaz:
https://doaj.org/article/a21b9e6913004e2a81f3a4e994607c9a
Autor:
Fernando Bril
Publikováno v:
Revista de la Sociedad Argentina de Diabetes, Vol 54, Iss 3Sup, Pp 40-40 (2020)
Symposium 9: Hepatic involvement in diabetes: beyond the liver Diabetes management of the patient with fatty liver thinking about the pandemic In the last years, we have witnessed great advances in pharmacological treatments for patients with type 2
Externí odkaz:
https://doaj.org/article/b82c57d8b513476c918b52d083db9659
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
Autor:
Marina Kawaguchi-Suzuki, Kenneth Cusi, Fernando Bril, Yan Gong, Taimour Langaee, Reginald F. Frye
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Pioglitazone is used effectively to treat non-alcoholic steatohepatitis (NASH), but there is marked variability in response. This study examined whether genetic variation contributes to pioglitazone response variability in patients with NASH. This ge
Externí odkaz:
https://doaj.org/article/925e93421a98439e92973a7e61b7a9af
Publikováno v:
Clinics in Liver Disease. 27:187-210
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08543b3eff27bdcdede6300a6d454017
https://doi.org/10.1016/j.cld.2023.01.002
https://doi.org/10.1016/j.cld.2023.01.002
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 108:42-51
Context The mechanisms leading to increased cardiovascular disease in patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis remain incompletely understood. Objective This study assessed HDL-bound proteins in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c6eb452c8f2f6801be2ebaf06315b3
https://doi.org/10.1210/clinem/dgac565
https://doi.org/10.1210/clinem/dgac565